Screening Adults With Obesity to Reduce Heart Failure Events

NAActive, not recruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

February 26, 2024

Primary Completion Date

July 8, 2026

Study Completion Date

July 8, 2026

Conditions
ObesityHeart Failure
Interventions
DIAGNOSTIC_TEST

Screening for heart failure

"• Anamnesis and Physical examination: Focus on signs of HF; will be performed by a trained employee.~• ECG: A standard 12-lead ECG will be recorded by a trained employee and will be interpreted by an experienced cardiologist.~• Echocardiography: A standard full echocardiogram will be acquired by a trained employee.~• Blood biomarkers: Venous blood samples will be taken and circulating levels of a broad range of markers related to obesity and/or heart failure will be determined. Also, an extra 10 mL blood sample will be drawn during the same venepuncture to be stored to determine additional biomarkers at a later stage.~• EQ-5D-5L questionnaire: EQ-5D-5L comprises five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which are divided into five degrees of severity, ranging from 'no problems' to 'extreme problems'."

Trial Locations (1)

3045 PM

Franciscus Gasthuis & Vlietland, Rotterdam

All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

collaborator

Star-shl

UNKNOWN

collaborator

De Leefstijlkliniek

UNKNOWN

collaborator

Leefstijl Centrum Rotterdam

UNKNOWN

collaborator

Voedingsadvies Broer

UNKNOWN

collaborator

Biotronik SE & Co. KG

INDUSTRY

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

Sanofi

INDUSTRY

collaborator

Novo Nordisk A/S

INDUSTRY

lead

Franciscus Gasthuis

OTHER